These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25298170)

  • 1. Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.
    Kim JY; Lee SH; Kim S; Kang T; Bae YT
    Eur Radiol; 2015 Apr; 25(4):1172-81. PubMed ID: 25298170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.
    Koo HR; Park JS; Kang KW; Cho N; Chang JM; Bae MS; Kim WH; Lee SH; Kim MY; Kim JY; Seo M; Moon WK
    Eur Radiol; 2014 Mar; 24(3):610-8. PubMed ID: 24097303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ; Kang KW; Chun IK; Cho N; Im SA; Jeong S; Lee S; Jung KC; Lee YS; Jeong JM; Lee DS; Chung JK; Moon WK
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1534-43. PubMed ID: 24652232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined
    Wu J; Zhang X; Jia Z; Zhou X; Qi R; Ji H; Sun J; Sun C; Teng Z; Lu G; Chen X
    Mol Pharm; 2022 Sep; 19(9):3405-3411. PubMed ID: 35972444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume-based metabolic parameter of breast cancer on preoperative 18F-FDG PET/CT could predict axillary lymph node metastasis.
    An YS; Kang DK; Jung Y; Kim TH
    Medicine (Baltimore); 2017 Nov; 96(45):e8557. PubMed ID: 29137072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):32-40. PubMed ID: 23929431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of preoperative
    Higuchi T; Nishimukai A; Ozawa H; Fujimoto Y; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Kitajima K; Fukushima K; Miyoshi Y
    Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.
    Kajáry K; Tőkés T; Dank M; Kulka J; Szakáll S; Lengyel Z
    Nucl Med Commun; 2015 Jan; 36(1):28-37. PubMed ID: 25299471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of 18F-fluorodeoxyglucose uptake with histopathological prognostic factors in breast carcinoma.
    Ekmekcioglu O; Aliyev A; Yilmaz S; Arslan E; Kaya R; Kocael P; Erkan ME; Halac M; Sonmezoglu K
    Nucl Med Commun; 2013 Nov; 34(11):1055-67. PubMed ID: 24025919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between ¹⁸F-FDG uptake and molecular subtype of breast cancer.
    Kitajima K; Fukushima K; Miyoshi Y; Nishimukai A; Hirota S; Igarashi Y; Katsuura T; Maruyama K; Hirota S
    Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1371-7. PubMed ID: 25947575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
    Straver ME; Aukema TS; Olmos RA; Rutgers EJ; Gilhuijs KG; Schot ME; Vogel WV; Peeters MJ
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1069-76. PubMed ID: 20130860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic activity of breast cancer metastatic lesions on positron emission tomography/computed tomography: comparison with histological and biological characteristics of primary tumor.
    Sobic Saranovic D; Stojiljkovic M; Susnjar S; Odalovic S; Artiko V; Pavlovic S; Grozdic-Milojevic I; Obradovic V
    Neoplasma; 2016; 63(2):313-21. PubMed ID: 26774154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Value of
    Song BI; Kim HW; Won KS
    Ann Surg Oncol; 2017 Aug; 24(8):2174-2181. PubMed ID: 28432480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.